
CAS 1193383-09-3
:Sortieren nach
Reinheit (%)
0
100
|
0
|
50
|
90
|
95
|
100
6 Produkte.
1H-Pyrazole-4-carboxylic acid, 1-[6-chloro-5-(trifluoromethoxy)-1H-benzimidazol-2-yl]-
CAS:Formel:C12H6ClF3N4O3Reinheit:%Farbe und Form:SolidMolekulargewicht:346.64921-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic Acid
CAS:1-(6-Chloro-5-(Trifluoromethoxy)-1H-Benzo[D]Imidazol-2-Yl)-1H-Pyrazole-4-Carboxylic AcidReinheit:98+%Molekulargewicht:346.65g/molJNJ-42041935
CAS:JNJ-42041935 (HIF-PHD Inhibitor II) is a potent (pKi = 7.3-7.9), 2-oxoglutarate competitive, reversible, and selective inhibitor of PHD enzymes.Formel:C12H6ClF3N4O3Reinheit:99.58% - ≥95%Farbe und Form:SolidMolekulargewicht:346.65JNJ 42041935
CAS:Kontrolliertes Produkt<p>Applications JNJ 42041935 is a selective hypoxia-inducible factor (HIF) prolyl hydroxylase (PHD) enzyme inhibitor. It can potentially be used for the treatment of inflammation-induced anemia.<br>References Barrett, T., et al.: Mol. Pharmacol., 79, 910 (2011); Thirstrup, K., et al.: Pharmacol. Res., 64, 268 (2011);<br></p>Formel:C12H6ClF3N4O3Farbe und Form:NeatMolekulargewicht:346.65JNJ 42041935
CAS:<p>JNJ 42041935 is a pharmacologic agent that inhibits the growth of cancer cells and may be used to treat chronic kidney disease. This drug binds to the extracellular matrix, which prevents the proliferation of cells in the tissue. JNJ 42041935 has been shown to inhibit the production of messenger RNA in urine samples taken from patients with chronic kidney disease. The clinical studies have shown that JNJ 42041935 can reduce the incidence of leukemia and blood disorders. The effective dose for this drug is not yet known, but it is thought that it may be around 1-10 mg/kg daily. It is also unknown how long JNJ 42041935 will remain in the body or what its excretion rate is.</p>Formel:C12H6ClF3N4O3Reinheit:Min. 95%Molekulargewicht:346.65 g/mol




